|
|
Agenerase (Amprenavir)
| Brand Name: |
Agenerase |
| Generic Name: |
Amprenavir, APV |
| Adult Single Dose: |
Eight 150-mg capsules (twice a day)
OR eight 150-mg capsules plus two 100-mg ritonavir capsules (once a
day) OR four 150-mg capsules plus one 100-mg ritonavir capsule (twice
a day) |
| Food & Liquid Restrictions: |
May be taken with or without food. High-fat meals should be avoided.
|
| Drug Class: |
PI |
The Basics
News
- Agenerase (Amprenavir) Oral Solution and 50-mg Capsules to Be Discontinued in the U.S. (October 2007)
To read PDF, click here
From GlaxoSmithKline
- FDA Bits: 3TC, Amprenavir and Nandrolone (September 2002)
Once-a-day dosing for 3TC (Epivir) approved; new interaction warnings for amprenavir (Agenerase); nandrolone decanoate returns to the U.S. market.
In HIV Treatment ALERTS!, from The Center for AIDS
- FDA Approves New Dosing for Amprenavir and Ritonavir Combination (March 8, 2002)
In AIDS Treatment News, from AIDS Treatment News
- New Dosing Regimen for Agenerase and Norvir (February 13, 2002)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- Amprenavir Oral Solution Warning (March 2001)
In What's New, from Project Inform
- What's New in Treatment Information? Amprenavir Oral Solution Warning (June 2000)
In What's New, from Project Inform
- Amprenavir (Agenerase®) Oral Solution: Warning for Some Patients (May 5, 2000)
In AIDS Treatment News, from AIDS Treatment News
- New Safety Warning for Liquid Amprenavir (May 5, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- Treatment Briefs: Agenerase Oral Solution Warning (Spring 2000)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Dose Adjustments When Using Amprenavir (September 1999)
In Project Inform Perspective, from Project Inform
- Amprenavir Approved: New (Possible) 2nd Generation PI Hits the Market (Summer 1999)
In STEP Perspective, from Seattle Treatment Education Project
- Fifth Protease Inhibitor Approved (June 1999)
In Body Positive, from Body Positive
- Amprenavir, New Protease Inhibitor, Approved (May 7, 1999)
From AIDS Treatment News
- FDA Approves an AIDS Drug From Vertex (April 19, 1999)
Approval of Agenerase, the fifth drug targeting HIV's protease enzyme.
From U.S. Centers for Disease Control and Prevention
- FDA Approves Amprenavir for HIV Infection (April 16, 1999)
From U.S. Food and Drug Administration
Research
- Dosing Agenerase + Kaletra -- Trying to Juggle, Walk and Chew Gum All at the Same Time (March/April 2004)
A study presented at CROI 2004 bolsters support for the use of therapeutic drug monitoring to customize dosing.
In Positively Aware, from Test Positive Aware Network
- Using Genotypic Inhibitory Quotient to Measure Response to Boosted-Amprenavir Regimen (July 15, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- GW433908 in ART-Naive Subjects: Absence of Resistance at 48 Weeks With Boosted Regimen and APV-Like Resistance Profile With Unboosted Regimen (February 11, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Fosamprenavir Enters the Home Stretch (December 2002)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Research From the 42nd ICAAC: Resistance Tests Compared; Amprenavir Is Guinea Pig (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- A Population Based-Analysis of Amprenavir Trough Concentrations Assessed in the Course of Therapeutic Drug Monitoring (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine: ESS40001 (CLASS) Preliminary 48-Week Results (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Efficacy and Safety of Amprenavir/Ritonavir 600/100 mg BID Compared to APV 1,200 mg BID in ART-Experienced and Naive Subjects: ESS40011 (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Potency and Tolerability of Once-a-Day, Directly Observed Therapy for Inner-City, Minority Patients (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Preliminary Results of Intensification Therapy With Amprenavir/Ritonavir in Two Different Doses: 1,200/200 QD vs. 600/100 BID in Heavily Pretreated Patients Failing HAART (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Decreased Plasma Concentrations of Amprenavir and Lopinavir in HIV Patients on This Combination (July 8, 2002)
In The XIV International AIDS Conference, from The Body PRO
- A New Look at Liver Toxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV (March 11, 2002)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- Amprenavir and Lipodystrophy (March 2002)
In Project Inform Perspective, from Project Inform
- An Assessment of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration of Two GW433908 (908) and Ritonavir (RTV) Regimens in Combination With Efavirenz (EFV) in Healthy Adult Subjects (APV10010) (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Molecular Mechanism of I50V, I54L and I54M Resistance to Amprenavir and Other HIV-1 Protease Inhibitors (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- In Vitro Model for Antiviral Activity for Amprenavir (APV)/Ritonavir (RTV) (December 19, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Efficacy, Safety and Amprenavir: Pharmacokinetic Responses of Twice-Daily APV and Ritonavir Regimens in HIV-1 Infected Treatment-Experienced Adults for 48 Weeks (ESS40006) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Impact on Fitness Conferred by Amprenavir Resistance Mutations (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Variations in HIV-1 Gag p6 Contribute to the Amprenavir-Specific Protease I50V Resistance Pathway (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Amprenavir (APV) Plasma and Intracellular Concentrations When Co-Administered With Ritonavir (RTV) in Twice- and Once-Daily Regimens in HIV-Infected Patients (December 16, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Novel Resistance Pattern Suggests Amprenavir May Be Unique After All (November 2001)
In HEPP News, from Brown Medical School
- Clinical Experience of Amprenavir (APV) Following Nelfinavir (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Final Results of a Pilot, 48-Week Study of Amprenavir/Abacavir/Lamivudine (APV/ABC/3TC) in ART-Naive Subjects with HIV-1 Infection (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Differential In Vitro Effects of Indinavir, Nelfinavir and Amprenavir On Cell Differentiation, Insulin Sensitivity and Apoptosis in an Adapted Adipose Cell Model -- Preventive Impact of Rosiglitazone (October 25, 2001)
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Prevalence of Phenotypic Resistance to Amprenavir in Protease-Inhibitor-Experienced Patients: Data from CNAB3008 (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Abacavir, Lamivudine and Amprenavir +/- Ritonavir Is a Potent and Well-Tolerated HAART Regimen in Therapy-Naive Subjects (Preliminary Results from GW Protocols) (COL30325) (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Comparison of QD Protease Inhibitors (PIs): Estimated Cmin/IC50 (IQ) After Missed Dose Shows Agenerase Advantage (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Influence of 50 mg, 100 mg and 200 mg of Ritonavir (RTV) on the Pharmacokinetics (PK) of Amprenavir (APV) After Multiple Doses in Healthy Volunteers for Once-Daily (QD) and Twice-Daily (BID) Regimens (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Monitoring Intracellular HIV-1 Replication in Blood and Lymphoid Tissue in Antiretroviral Naive Subjects Receiving Amprenavir (APV), Abacavir (ABC), and 3TC (COLA3003 Study) (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Use of Trizivir to Simplify Therapy in HAART-Experienced Patients With Long-Term Suppression of HIV-RNA: TRIZAL Study (AZL30002) -- 24-Week Results (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Therapeutic Drug Monitoring of Amprenavir Combined With Ritonavir as Salvage Therapy in HIV-1-Infected Patients (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
|
|
